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broad definition of pathology, we here review the “neuropa-
thology of stress” and focus on structural consequences of 
stress exposure for different regions of the rodent, primate 
and human brain. We discuss cytoarchitectural, neuropatho-
logical and structural plasticity measures as well as more 
recent neuroimaging techniques that allow direct moni-
toring of the spatiotemporal effects of stress and the role 
of different CNS structures in the regulation of the hypo-
thalamic–pituitary–adrenal axis in human brain. We focus 
on the hypothalamus, hippocampus, amygdala, nucleus 
accumbens, prefrontal and orbitofrontal cortex, key brain 
regions that not only modulate emotions and cognition but 
also the response to stress itself, and discuss disorders like 
Abstract Environmental challenges are part of daily life 
for any individual. In fact, stress appears to be increas-
ingly present in our modern, and demanding, industrialized 
society. Virtually every aspect of our body and brain can 
be influenced by stress and although its effects are partly 
mediated by powerful corticosteroid hormones that target 
the nervous system, relatively little is known about when, 
and how, the effects of stress shift from being beneficial 
and protective to becoming deleterious. Decades of stress 
research have provided valuable insights into whether 
stress can directly induce dysfunction and/or pathological 
alterations, which elements of stress exposure are respon-
sible, and which structural substrates are involved. Using a 
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depression, post-traumatic stress disorder, Cushing syn-
drome and dementia.
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Aβ  Amyloid beta (β) protein
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APP  Amyloid precursor protein
AQP4  Water channel aquaporin-4
AR  Androgen receptor
AVP  Arginine vasopressin
BD  Bipolar depression
BDNF  Brain-derived neurotrophic factor
BLA  Basolateral amygdala
BST  Bed nucleus of the stria terminalis
CBG  Glucocorticoid binding globulins
CDK5  Cyclin-dependent kinase 5 (cell division pro-
tein kinase 5)
CRH  Corticotropin-releasing hormone
CRH-R  Corticotropin-releasing hormone receptor
DHEA  Dehydro-epi-androsterone
DHEAS  Dehydro-epi-androsterone sulphate
DL–PFC  Dorsolateral prefrontal cortex
EAAT  Excitatory amino acid transporters
EGF  Epidermal growth factor
ER-α  Estrogen receptor-alpha
GAD  Glutamic acid decarboxylase
GC  Glucocorticoid hormone
GFAP  Glial fibrillary acidic protein
GR  Glucocorticoid receptor
GS  Glutamine synthetase
fMRI  Functional magnetic resonance imaging
H-MRS  Proton magnetic resonance spectroscopy
HPA  Hypothalamic–pituitary–adrenal
IL-1β  Interleukin 1-beta
IGF-1  Insulin-like growth factor-1
LTD  Long-term depression
LTP  Long-term potentiation
MDD  Major depressive disorder
mPFC  Medial prefrontal cortex
MR  Mineralocorticoid receptor
MRI  Magnetic resonance imaging
NAc  Nucleus accumbens
NGF  Nerve growth factor
NPCs  Neural progenitor cells
OXT  Oxytocin
pgACC  Pregenual anterior cingulate cortex
PFC  Prefrontal cortex
PSD-95  Post-synaptic density-95
PTSD  Post-traumatic stress disorder
PVN  Paraventricular nucleus of the hypothalamus
SNPs  Single-nucleotide polymorphisms
SSRI  Selective serotonin reuptake inhibitor
SVZ  Subventricular zone
UD  Unipolar depression
VEGF  Vascular endothelial growth factor
Stress and the brain
The concept of stress
Whenever an endogenous or exogenous challenge is per-
ceived as unpleasant, aversive or threatening, a series of 
systems and processes is activated that generates a coordi-
nated response to that particular challenge, or stressor. This 
so-called stress response, an integral part of any adaptive 
biological system, is conserved throughout evolution. It is 
particularly active when an individual’s homeostasis, well-
being, overall health or survival is threatened. An unpleas-
ant surprise, relational or financial problems, the loss of a 
loved one, bereavement, unpredictability, an acute threat, 
e.g., when faced with an animal predator, or with psycho-
social demand in humans, can all initiate a stress response. 
The same is true for perturbations of a more biological 
nature, such as an energy crisis, physical injury, hemor-
rhage or inflammation.
According to the popular press, stress is ever present in 
our modern, performance oriented and demanding society 
[109]. Stress contributes to several disabilities worldwide 
and as such represents a severe economical burden. The 
WHO expects that mental disease, including stress-related 
disorders, will be the second leading cause of disabilities 
by 2020. In the US, job stress alone, e.g., has been esti-
mated to cost several hundred billions of USD every year in 
absenteeism, turnover, diminished productivity and medi-
cal, legal and insurance costs.
Stress, however, is no single entity and several different 
types of stressors can be distinguished: stressful challenges 
can be acute (being confronted with a predator or giving 
an important oral presentation) or of a chronic nature (liv-
ing in poverty or in a broken family). It may occur only 
once, or may rather take place in a repetitive manner, that 
can be anticipated. Conversely, stress can be unpredict-
able and uncontrollable, mild or severe, and occurring in 
or out of context, e.g., of a learning experience [93, 102]. 
In addition, how stress exposure is actually perceived by 
an individual varies greatly, as does the persistence of its 
consequences.
Importantly, physiological ‘stress’ responses also occur 
following rewarding, “positive” and appetitive stimuli (e.g., 
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winning a competition, sexual activity). Although they 
are often not considered to be stressors in classic, gener-
ally “negative”, terms, the physiological responses elicited 
by them can be as large as those seen after more aversive 
stimuli [104]. For the purpose of definition, a stressor in 
the context of this review will refer to any environmental 
demand that exceeds the physiological regulatory capacity 
of an organism, in particular during situations of unpredict-
ability and uncontrollability. They are characterized by the 
absence of an anticipatory response (unpredictable), or a 
reduced recovery (uncontrollable) of the neuroendocrine 
reactions to stress. Taken together, depending on the type 
of stressor, various signals converge to orchestrate an inte-
grated stress response that ‘resets’ many peripheral and 
central processes and allow an individual to adapt to the 
changes in its environment and thus to restore homeostasis.
The physiological stress response can be divided into 
two different time domains with a very quick response and 
a delayed response. The first phase of the stress response 
is considered the “alarm reaction” or the “fight-fright-or-
flight” response, which involves the rapid activation of the 
autonomic nervous system (ANS) that causes the release of 
epinephrine and norepinephrine from the adrenal medulla. 
These hormones quickly elevate basal metabolic rate, blood 
pressure and respiration, and increase blood flow to the 
more vital organs that are essential for the “fight-or-flight” 
response, such as the heart and skeletal muscles. At a later 
stage, the hypothalamic–pituitary–adrenal (HPA) axis is 
activated as well. In this classic neuroendocrine circuit, 
limbic and hypothalamic brain structures coordinate emo-
tional, cognitive, neuroendocrine and autonomic inputs, 
which together determine the magnitude and specificity of 
an individual’s behavioral, neural and hormonal responses 
to stress.
This second response is mediated by glucocorticoid 
(GC) hormones (corticosterone in rodents and cortisol 
in humans) which generally act in a slow, genomic man-
ner as transcriptional regulators of glucocorticoid respon-
sive genes. Fast (non-genomic) GC actions have also been 
described and their actions are mediated by putative mem-
brane-bound receptors. It should be emphasized that other 
signalling pathways act in concert with the HPA axis like 
the gonadal axis, the adipose axis, and the immune system. 
All these help to direct energy resources such that atten-
tion can be focused on the most urgent and important ele-
ments of the challenge while other, less urgent functions, 
e.g., food intake, digestion or reproduction, are temporar-
ily suppressed [93]. The profound change in activational 
patterns that is induced by perceiving a situation as stress-
ful can nowadays be visualized by functional magnetic 
resonance imaging (fMRI) studies, and as can be seen in 
Fig. 1, encompasses a variety of limbic system and frontal 
lobe structures, including hippocampus, amygdala and the 
anterior cingulate cortex. Throughout the text, we focus on 
the HPA axis, because this system is most heavily investi-
gated, but it should be emphasized that several other sys-
tems contribute to the stress response as well (see “Inflam-
matory changes and depression”, “Gender differences in 
depression: relationship with HPA axis activity”, “The glu-
tamatergic and GABAergic systems in depression”, “Glial 
plasticity”, “Water content, volume changes and altered 
vasculature”).
HPA axis, stress hormones and their receptors
HPA axis activation is triggered by corticotropin-releasing 
hormone (CRH) in the paraventricular nucleus (PVN) that 
induces adrenocorticotropic hormone (ACTH) release from 
the pituitary, which in turn releases GCs from the adre-
nal. Regulation occurs through negative feedback after 
GC binding to high-affinity mineralocorticoid (MR) and 
lower affinity glucocorticoid receptors (GR) [47]. HPA axis 
activity is not only affected by stress, (see “Inflammatory 
changes and depression”) and a bi-directional communica-
tion exists, e.g., between the immune and neuroendocrine 
stress systems.
The GR helps to maintain GC levels within physiologi-
cal limits [57, 104]. Aberrant GR expression has been impli-
cated in stress resistance, anxiety and depression [47, 172, 
234]. GC plasma levels are under circadian and ultradian 
control [115, 163]. Together, MR and GR determine sensi-
tivity of the brain to stress [77, 135, 160, 203] and thereby 
modulate attention, vigilance, behavior and memory forma-
tion and eventually adaptation and coping with stress.
Fig. 1  Identification of the brain regions that show activational 
changes during acute stress. Data are based on averages of 21 healthy 
subjects who were exposed to the Montreal Imaging Stress Task and 
showed subsequent cortisol increases, for details see [159]. Activation 
is prominent in a variety of limbic system and frontal lobe structures, 
including hippocampus, amygdala and the anterior cingulate cortex
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Glucocorticoid hormone actions and hippocampal 
pathology; the ‘glucocorticoid cascade’ hypothesis
Upon their release in the periphery, GCs enable an indi-
vidual to engage in an adaptive response to a stressor by 
affecting energy and lipid metabolism, among others. The 
large numbers of GRs in the brain, and particularly the hip-
pocampus, make it vulnerable to elevated GC levels [47, 
120, 209]. The GR occurs in at least two isoforms (GRal-
pha and GRbeta), with the GRalpha isoform being the 
most predominant one in brain. In addition to rodent stud-
ies, [171] several human brain regions express GR and MR 
[77, 162, 189, 233]. In humans, considerable diversity of 
GR and MR transcripts exists [49, 100], which includes 
13 exon 1 mRNA variants and 8 N-terminal variants, that 
arise from the GRalpha isoform. In the human hypothala-
mus, GRalpha protein is selectively expressed in CRH-
containing parvocellular, but not magnocellular, neurons of 
the PVN [231]. Application of exogenous, synthetic GCs 
strongly suppresses CRH and vasopressin production in 
neurons of the human PVN (Fig. 2) [59], whereas oxytocin 
(OXT) neurons are not affected.
In contrast to the relative paucity of GR in the rhesus 
monkey [175], the human hippocampus shows abundant 
GR protein expression in CA1 and DG neurons, although 
the CA3 subregion has lower levels. GR is additionally 
expressed in astrocytes and overall GR levels remain sta-
ble with age. Increases have been found in the hippocam-
pus and amygdala of patients with major depression (MDD) 
[229, 231, 232]. Thus, even though less is known about the 
MR [162], the prominent expression of GR in human brain 
makes these regions important targets for stress exposure [2, 
93, 100]. Whereas acute and short-term stress is generally 
considered beneficial and adaptive, chronic stress may cause 
an MR/GR imbalance or down-regulation [47, 162] which 
can alter HPA feedback and result in overexposure of the 
brain and peripheral tissues to these powerful steroids.
When considering neuropathological aspects of stress, 
earlier animal experiments had reported brain damage after 
prolonged periods of stress, especially in aged animals and 
mainly in the hippocampus. For example, Landfield et al. 
[107] showed that cumulative GC exposure influenced 
hippocampal viability and compromised cognition. Sub-
sequently, Sapolsky et al. [178, 182] reported that chronic 
stress causes a loss of pyramidal neurons in the hippocam-
pus, accompanied by cognitive deficits in rats. Another 
study described that training rats for 6 months in a two-way 
shuttle escape task, using low intensity foot shock stress 
(4 h/days) resulted in endogenous hypercortisolism and 
CA1 pyramidal neuronal loss in senescent rats [98], while 
others reported reactive gliosis, reduced dendritic branch-
ing and reductions in volume and in CA1/3 cell numbers 
[181, 183].
The hippocampus was previously thought to inhibit CRH 
activity directly, and given its high MR and GR density 
[171, 189, 231], damage to the hippocampus was expected 
to cause a disinhibition of CRH activity, thus increasing the 
drive on the HPA axis, which in turn would further stimu-
late GC levels and aggravate hippocampal damage. This 
feed-forward “glucocorticoid cascade hypothesis” was 
proposed to be a pathogenic mechanism underlying stress 
effects on the brain, and considered relevant for human dis-
orders associated with peripheral HPA axis changes that 
were paralleled by structural changes in the hippocampus, 
like Alzheimer’s disease (AD), post-traumatic stress disor-
der (PTSD), Cushing’s disease and depression [182].
These interpretations were supported by studies on subor-
dinate, wild-born vervet monkeys that had experienced pro-
longed, severe social stress in captivity and that displayed 
post-mortem adrenal hypertrophy. Although the coincident 
hippocampal degeneration in these animals was consistent 
with the glucocorticoid cascade hypothesis, the morphologi-
cal alterations and neuron loss in these, and also in other 
non-human primates implanted with cortisol pellets in their 
hippocampi [183], were most pronounced in CA neurons 
[217], brain regions particularly sensitive to pressure arti-
facts; after death, the soft tissue of the brain can be com-
pressed by its own weight or by manipulation during brain 
collection, which refers to “post-mortem compression”.
While the initial studies had used rather extreme, physi-
cal stressors or extremely high pharmacological GC con-
centrations [101, 181], later studies in non-human primates 
and rodents that used more relevant psychosocial stressors 
[112, 219, 223], added conflicting data insofar that they did 
not observe massive neuronal loss or obvious neuropathol-
ogy following chronic stress when this was assessed using 
unbiased stereological tools [157, 201, 223]. For example, 
when adult male rats were chronically treated with the 
selective GR agonist dexamethasone, with dexamethasone 
plus the selective MR agonist aldosterone, or with supra-
physiological doses of corticosterone, only dexamethasone 
treatment reduced DG granule and CA3 pyramidal cell 
numbers [202]. However, this synthetic steroid differs from 
the endogenous corticosterone in terms of brain penetrance 
and retention and although it can induce cognitive deficits 
in aged mice [238], it did not influence the CA1 or hilar 
subfields. In contrast to dexamethasone, animals injected 
with corticosterone failed to reveal any change in cell num-
ber in any of the hippocampal subfields, although volume 
reductions in hilus and CA3 were observed [201]. Also in 
tree shrews exposed to chronic subordination stress, the 
CA1 and CA3 pyramidal neuron numbers were not dif-
ferent from controls, despite elevated cortisol levels [223]. 
Chronic studies in pigs, non-human primates and chicka-
dees yielded similar results while changes in apoptosis 
were also not demonstrated [112, 157, 219].
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It is now known that the tonic inhibitory control on HPA 
axis activity [82] is exerted through several, often indirect, 
neural pathways including the bed nucleus of the stria ter-
minalis (BST), the amygdala and the endocannabinoid sys-
tem [212, 221]. The GC-mediated negative feedback of the 
HPA axis thus takes place at several levels, including the 
hypothalamus and pituitary, and not only at the hippocam-
pus [82, 84]. Also, although GCs target hippocampal cells, 
they can increase vulnerability to, but not directly cause, 
subsequent insults [33]. Moreover, an absence of massive 
structural changes after GC exposure does not necessarily 
imply that no functional, molecular or changes in respon-
sivity [43] are induced. Furthermore, variables like genetic 
risk factors, early life programming and structural plastic-
ity were not considered at the time. As a consequence, the 
GC cascade hypothesis has been refined and rephrased over 
time [31, 119, 134, 154, 160]. Together with the corticos-
teroid receptor hypothesis of depression [87] and the reali-
zation that GCs are on the other hand, essential for, e.g., 
dentate viability [197], it has sparked the development of 
drugs selectively targeting specific stress system compo-
nents [88, 188, 243].
Fig. 2  Exogenous or synthetic glucocorticoid treatment affects the 
human brain and reduces the numbers of CRH-immunoreactive cells 
in the hypothalamic PVN (a) but has no effect on oxytocin immu-
noreactivity in the PVN of corticosteroid-exposed subjects (d; CST). 
Reproduced, with permission, from [59]
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Molecular, cellular and functional changes 
in stress‑related psychiatric disorders
It is difficult to describe the complete and exact neuro-
pathological consequences of stress exposure in the human 
brain as stress can occur in so many different forms and 
depends on an individuals coping strategy and stress sensi-
tivity. Also, there is no single unique disease or direct neu-
ropathological hallmark that is always, only and directly, 
caused by stress exposure per se. Notably, many of the 
stress-induced changes are plastic and reversible in nature, 
for this phenomena we use the term “neuroplasticity”, 
which refers to the general capacity of the brain to adapt 
functionally or structurally to a change in demands, and 
we further specify when particular forms of plasticity are 
discussed.
However, severe or prolonged stress is well known to 
increase the risk to develop psychopathologies such as 
PTSD, depression, schizophrenia or anxiety disorders in 
susceptible individuals and may even trigger psychotic epi-
sodes. Clear brain changes have been described in these 
conditions and our aim is to summarize those. We focus 
on disorders where the relationship between stress and the 
disease occurrence is well documented and where obvious 
structural alterations have been reported, like in depression, 
PTSD, Alzheimer’s and Cushing’s disease.
Stress-related changes in major depressive disorder (MDD)
Stress is the most common risk factor for the development 
of mood disorders like MDD that are thought to result from 
interactions between genetic predispositions and the envi-
ronment [173]. Especially stressful life events experienced 
during early childhood or adolescence can significantly 
increase the risk to develop depression [78]. Indeed, in a 
large proportion of depressed patients the HPA axis acti-
vation and GC feedback resistance is common. This is 
reflected by the high percentage of dexamethasone non-
suppressors in this population as well as hypertrophy of 
the adrenals and pituitary and increased plasma levels of 
cortisol, particularly during the through of the circadian 
rhythm, and increases in CRH and AVP expression in the 
PVN [209]. Notably, depressed subjects show remarkable 
heterogeneity in neuroendocrine function and the propor-
tion of depressed individuals demonstrating overt HPA axis 
abnormalities may range from 35 to 65 %.
Hypothalamic neuropeptide changes in depression
CRH in depression CRH-expressing neurons in the hypo-
thalamic PVN are the central driving force of the HPA 
axis. The number of CRH expressing neurons, the num-
ber of CRH neurons co-expressing AVP, and the amount 
of CRH-mRNA in the PVN are significantly increased in 
depressed subjects, independent of whether they died dur-
ing a depressive state or not (Fig. 3) [166]. Since intrac-
erebroventricular injection of CRH induces symptoms of 
depression in rodent [87], centrally released CRH may be 
implicated in depression etiology. During post-natal devel-
opment of the stress system, CRH controls HPA axis activ-
ity and mediates effects of early disturbances like maternal 
deprivation, through the CRH receptor CRH-R1. Both basic 
and clinical studies further suggest that disrupting CRH 
signaling through CRH-R1 ameliorates stress-related clini-
cal conditions. Although CRH in CSF is also derived from 
other brain areas like the thalamus, CRH concentrations of 
healthy controls and depressed patients decrease after treat-
ment with antidepressant drugs [83]. Lastly, in depressed 
patients the significantly increased CRH-mRNA levels in 
the PVN are accompanied by an increased expression of 
genes involved in CRH activation, such as CRH-R1, MR, 
estrogen receptor-alpha (ER-α) and AVPR1a, and with a 
significantly decreased expression of genes involved in the 
inhibition of CRH neurons, such as the androgen receptor 
(AR) mRNA [8, 228]. These findings [228] raise the pos-
Fig. 3  Quantification of glutamic acid decarboxylase (GAD)65/67-
immunoreactivity (GAD-ir) (a), the total number of corticotropin-
releasing hormone (CRH-ir) neurons in the hypothalamic paraven-
tricular nucleus (PVN) (b) of depressed patients and controls. Con 
controls, Dep depression, MDD major depressive disorder, BD bipo-
lar disorder. Significant increases are found in total numbers of CRH-
ir in the depressed, major depressed and bipolar groups (b, see also 
[166]), whereas GAD65/67-ir is significantly reduced in the major 
depressed group (a). From [65], with permission
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sibility that a disturbed receptor balance in the PVN contrib-
utes to a CRH-mediated HPA axis activation in depression.
Arginine vasopressin (AVP), stress and depression There 
are at least four different vasopressinergic systems inti-
mately involved in the signs and symptoms of depression 
[209]. First, AVP is produced by the magnocellular neurons 
of the hypothalamic SON and PVN, whose axons run to 
the neurohypophysis where they release AVP and OXT into 
the general circulation. Circulating AVP targets the anterior 
pituitary while high levels also affect mood. Secondly, the 
parvocellular neurons of the PVN secrete CRH and AVP 
also as neurohormones from their axons in the median 
eminence, into the portal capillaries that transport them to 
the anterior lobe of the pituitary. AVP strongly potentiates 
ACTH-releasing activity.
Third, vasopressinergic fibers project from the hypothal-
amus to subregions of the hippocampus, septum, amygdala 
and brainstem, where AVP serves as a neurotransmitter/
neuromodulator via AVPR1a and AVPR1b receptors. More-
over, magnocellular neurons release AVP from their den-
drites and somata to act as local neuromodulators on recep-
tors close to their site of release. Fourth, AVP is released 
into the brain with a circadian rhythm by neurons of the 
biological clock or SCN, which shows significant changes 
in depression. Once overexpressed, AVP may contribute to 
hyper-anxiety and depression-like behaviors, whereas AVP 
deficits may, in addition to diabetes insipidus, cause signs 
of hypo-anxiety and disturbed rhythmicity [108].
A misbalance of multiple genes involved in HPA axis 
regulation may occur in the PVN in depression with a pos-
sible role for AVPR1a [228]. Since also early types of stress 
can epigenetically program the AVP gene in a long-lasting 
manner [139, 140], the AVP-driven HPA axis hyperactivity 
in depression is receiving more attention [136].
In the PVN of depressed patients, the number of AVP 
and OXT protein expressing neurons is increased while for 
AVP mRNA, a 60 % increase in expression was found in 
the SON in melancholic but not in non-melancholic depres-
sion [136]. Enhanced AVP mRNA production leads to 
increased plasma levels of AVP [220] that have been related 
to an enhanced suicide risk in depression, as well as to an 
anxious-retarded type of depression, psychomotor retarda-
tion and memory disturbances in depression.
Hippocampal changes in depressed patients
Maladaptive responses to stress and the associated GC 
hypersecretion can induce hyperemotional states, mood 
dysfunction and cognitive impairments in depressed 
patients. This is often paralleled by volume changes in 
various brain regions including the hippocampus. In early 
studies, considerable variation was found in hippocampal 
volume in depression [124, 160]. Several explanations for 
this variation have been put forward including the higher 
spatial resolution in the more recent studies or differences 
in disease duration [195], anatomical delineation [179], 
lateralization, early life conditions and genotype [22, 158, 
160, 215], the presence of abuse [215] and/or pharmaco-
logical treatments [116]. Hippocampal volume reductions 
in depression are by now one of the best-replicated find-
ings in biological psychiatry [97], but whether it is cause or 
consequence of the disorder remains unclear. Predictors of 
lower hippocampal volumes in patients were: a more exten-
sive depressive episode duration and recurrence, the size of 
their integrated cortisol responses and a history of early life 
stress [46, 62, 160, 226], while a smaller hippocampal vol-
ume could also predispose for the development of psycho-
pathology [180].
Although classic MRI studies generally demonstrated 
a lower volume of the entire hippocampus in depression, 
spatial resolution generally precluded in vivo measurement 
of distinct hippocampal subfields, even though preclinical 
and some post-mortem studies indicated that chronic stress 
and depression affect hippocampal subfields, and different 
structural substrates, to a different extent. In addition to 
subfields across its transversal axis, the hippocampus also 
shows topographical segregation along its longitudinal axis 
[61]. Improved spatial resolution of high field strength MRI 
has now enabled to identify connectivity changes [245] and 
detailed measurements of subfield areas [90, 92, 235]. They 
revealed that the mean volumes of the DG and CA1-3 sub-
region were smaller in non-medicated or recently unmedi-
cated depressed patients than in healthy controls. Along the 
longitudinal axis, a smaller volume was mainly found pos-
teriorly, i.e., in the hippocampal body and tail, rather than 
anteriorly in the hippocampal head [90].
Of interest, both the subfield and posterior hippocampal 
volume reductions were seen only in unmedicated depres-
sion but were absent in patients treated with antidepres-
sants. The posterior hippocampus may thus be particularly 
susceptible to volume changes [130, 143, 184], the extent 
of which may even predict a worse treatment outcome 
[128]. Furthermore, successful long-term antidepressant 
treatment also seems to increase posterior hippocampal 
volume [184]. In agreement with preclinical studies of 
chronic stress, decreases in CA3 volumes were shown [90] 
that, based on rodent studies, it could be related to different 
structural substrates, as will be discussed below.
In a recent post-mortem study, hippocampal tissue of 
17 pairs of MDD and control subjects, all around 50 years 
of age, were analyzed stereologically. While hippocampal 
volume in all MDD subjects was not significantly smaller 
compared to control subjects, total volume in MDD was 
decreased with duration of depressive illness. Also, there 
was no significant difference between MDD and controls 
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in total number or density of the pyramidal neurons and 
granule cells or glial cells in the CA1, CA2/3, hilus, or DG 
subregion [29]. However, CA1 pyramidal neuron density 
increased with duration of illness in MDD and both gran-
ule cell and glial cell numbers increased with age in MDD 
patients on medication which may reflect proliferative 
effects of antidepressants (see Fig. 4, “Adult hippocampal 
neurogenesis”). This suggests that reductions in volume 
parallel to increased cellular densities are best explained 
by assuming cell shrinkage and hence changes in neuro-
pil rather than cell loss [29, 206]. Also changes in water 
content may be implicated (see “Water content, volume 
changes and altered vasculature”).
Imaging studies in patients with stress-related affective 
and emotional disorders have shown that also the volume 
of structures other than the hippocampus like the PFC, cin-
gulate cortex, hypothalamus and amygdala, as well as their 
interactions and coherence, is altered by stress [45, 147, 
160, 200]. Finally, it should be noted that hippocampal 
shrinkage is not stress specific and has also been reported 
in several other brain disorders including schizophrenia, 
dementia, Parkinson’s and Huntington’s diseases, epilepsy 
and alcoholism [36].
Stress effects on the amygdala
While the hippocampus mediates spatiotemporal aspects 
of behavioral impairment, the amygdala contributes to the 
affective and emotional aspects of cognition [110]. Clini-
cal studies have shown increases, decreases or no change in 
Fig. 4  Changes in proliferation in the human brain of depressed 
and anti-depressant-treated patients. a Cells immunopositive for the 
cell cycle marker minichromosome maintenance protein 2 (MCM2) 
that is involved in the control of DNA replication. In the hippocam-
pus, many MCM2-immunopositive cells and doublets (arrows) are 
observed in cortical tissue of a 2-year-old subject that served as posi-
tive control. b MCM2-ir cell numbers are strongly reduced to very 
low numbers (arrow) in a 69-year-old control subject. c MCM2-ir 
doublet of 2 still closely attached cells that appear to be about to sep-
arate in the hippocampus of a depressed patient (arrow), cresyl violet 
counterstain. Cells are viewed under a 10× magnification (a, b) or at 
63× (c). d Graphs depicting numbers of MCM2 and phosphorylated 
histone H3 (PH3) immunopositive cells (the latter marker reflecting 
late G2 and mitotic phase of cell division). PH3 immunoreactive cells 
in the subgranular zone and granular cell layer of the dentate gyrus, 
normalized to the surface area of the GCL and expressed per square 
micrometer. A significant reduction is found for MCM2, but not PH3, 
in a cohort of 10 elderly (average age of 68 years) depressed patients 
compared to 10 controls. e Neural progenitor and f dividing cells 
(Nestin and Ki-67 as respective immunocytochemical markers) are 
increased in the dentate gyrus of a younger cohort of (average ages 
of 40 and 54 years) of patients with major depressive disorder (MDD) 
who were treated with antidepressants compared to untreated MDDs 
and control subjects. Progenitor numbers (e, Nestin-ir) were higher 
in MDD patients treated with tryciclics (TCA) or with selective 
serotonin reuptake inhibitors (SSRI), compared to untreated MDD 
and Control cases whereas the numbers of dividing cells (f, Ki-67-
ir) were higher only in the TCA but not SSRI-treated group (n = 5–7 
cases per subgroup). Reproduced, with permission, from [15, 121]. 
[121] was used for (a–d) and [15] was used for (e, f)
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volume of the amygdala in MDD [23] and a meta-analysis 
even found no changes in amygdala volume in depressed 
patients although increases in cerebral blood flow to the 
amygdala, a correlate of neuronal activity were reported 
[54]. Recent experimental studies have identified cellu-
lar and molecular correlates of stress-induced amygdaloid 
plasticity that may underlie anxiety and depressive-like 
behavior. Animals exposed to chronic stress exhibited 
enhanced anxiety in the elevated plus-maze while at the 
cellular level, a persistent increase in dendritic arboriza-
tion and higher spine density was found across the primary 
and secondary branches of the basolateral amygdala (BLA) 
spiny neurons and even spine formation was induced [137].
This dendritic hypertrophy in the BLA after stress is 
distinct from the retractions seen in the hippocampal CA3, 
which is reversible after a stress-free period [225]. In con-
trast, the BLA does not re-adjust morphologically or func-
tionally after such a recovery period [137, 225]. This adds 
to accumulating evidence that structural encoding of aver-
sive experiences, through enhanced availability of post-
synaptic dendritic surface and synaptic inputs on principal 
neurons of the BLA, may facilitate symptoms of chronic 
anxiety and disorders like MDD and PTSD by enhancing 
synaptic connectivity in the BLA [154].
Such changes resemble findings in humans where larger 
amygdala volumes have been found, partly related to early 
stress exposure [125, 160]. The apparently conflicting clini-
cal and basic findings could be due to heterogeneous clini-
cal populations, where depression is comorbid with other 
psychiatric illness, or medication effects, as some patients 
were undergoing treatment during the investigations. At the 
same time, the stress paradigms used in basic research are 
incomplete models not capable of fully recapitulating the 
human disease state. Furthermore, most of the basic science 
findings were gathered from adult rodent stress and did not 
take into account early stress, which has been implicated in 
depression vulnerability [122].
The prefrontal cortex (PFC)
The PFC participates in cognitive, socio-emotional and 
executive functions that are sensitive to stress [4, 26, 40, 
50]. Furthermore, the PFC modulates autonomic and neu-
roendocrine responses to stress [82, 151]. As the human 
PFC is one of the last regions to complete maturation, it 
contains neurons with more complex dendritic trees than 
earlier maturing cortical structures. This prolonged devel-
opment makes the PFC susceptible to disruption and it 
indeed is affected in developmental neuropsychiatric dis-
orders like autism and schizophrenia [214]. GRs and MRs 
are abundantly expressed by neurons and glia in the PFC of 
rodents and primates [175] and regulated by stress [153]. 
A recent human study investigated developmental changes 
in GR expression in the dorsolateral PFC from infancy 
to adulthood and found dynamic patterns of GR isoform 
expression across the lifespan, suggesting that the neona-
tal and late adolescent periods represent vulnerability win-
dows to stress during human cortical development [191]. 
Furthermore, abnormal GR isoform expression levels have 
been found in the PFC of patients with psychiatric disor-
ders like schizophrenia, bipolar and major depressive dis-
orders [162, 190, 192]. Transcript level of MR was signifi-
cantly decreased, while the ratio of GRα to MR mRNA was 
increased in the anterior cingulate cortex (ACC) and the 
dorsolateral PFC (DL–PFC) of depressed patients. Thus, 
a selective disturbance of MR and of GRα/MR ratio may 
exist in the ACC/DL–PFC in depression that is inversely 
correlated to the corresponding levels in the PVN and may 
thereby contribute to HPA axis hyperactivity and depres-
sion etiology [162].
A large body of evidence further demonstrates that 
repeated stressful experiences have a profound impact on 
neuronal plasticity in the PFC. The most thoroughly inves-
tigated neuromorphological change is the regression of the 
geometrical length of apical dendrites of pyramidal neu-
rons in layers II–III of the mPFC [26, 40, 164]. The main 
results from these studies are a significant reduction in total 
dendritic length of 20–35 % with a significant decrease in 
branching and spine density of the distal apical dendrites. 
These chronic stress-induced effects are likely to be medi-
ated partially by the activation of GRs and NMDA recep-
tors [156] because artificially elevated levels of GCs result 
in morphological changes similar to those seen follow-
ing chronic stress exposure [26, 40, 164], while blocking 
NMDA receptors could prevent these stress-induced effects 
[132]. It also appears that these changes are plastic and not 
degenerative in nature, because they reverse spontaneously 
after a recovery period [71, 165], at least when animals are 
young, as middle-aged and aged rats failed to show this 
reversible dendritic remodeling [13].
Notably, most rodent studies [26, 40, 164] report a sig-
nificant impact of stress on the apical but not basal den-
drites. However, the only comparable human study that 
examined dendritic branching of pyramidal neurons in the 
ACC of depressed suicides found significantly reduced 
numbers of third-order branches in the basilar dendritic 
arbor [81]. These data are the first evidence of altered cor-
tical dendritic branching in a psychiatric disorder. As the 
proximal dendritic branches grow during perinatal devel-
opment, and are generally less plastic at maturity than the 
more distal segments, this led the authors to speculate that 
differences in dendritic branching may reflect a biologi-
cal predisposition to depression and suicide [81], or could 
result from perinatal stress exposure.
Notably, not only the glutamatergic pyramidal cells are 
affected by chronic stress, but also GABAergic interneurons 
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undergo dendritic reorganization in the mPFC and dendritic 
hypertrophy was found in a subpopulation of interneurons 
identified as Martinotti cells [68]. Chronic adverse experi-
ences further decrease GAD67 expression levels and the 
number of GAD67 expressing neurons [68, 185]. GAD67 
is the 67 kDa isoform of glutamate decarboxylase enzyme 
which synthetizes GABA and is a marker for GABAergic 
neurons. Chronic stress also decreased the number of par-
valbumin-positive interneurons in the PFC [185].
Not only PFC neurons are affected by chronic stress, 
but glial cells as well. Stress, e.g., inhibits gliogenesis in 
the PFC [39], results in impaired activity of microglia [86] 
and in a profound shortening of astrocytic branching and 
process length, as well as reduced GFAP expression [216]. 
These findings are in line with the astrocytic pathology 
in the PFC of depressed patients, that includes reduced 
astroglial cell numbers and related markers [167]. Finally, 
many of the cellular changes after stress can be hemisphere 
specific, and stress often abolishes or even reverses asym-
metries at the cellular level [39, 40].
Studies on the mPFC have been critical in showing that 
the impact of stress on one brain region can spread to other 
areas that are synaptically linked [200] involving, e.g., the 
corticostriatal network and indeed stress shifts decision-
making to more habitual processing [50]. Thus, chronic 
stress-induced morphological and functional changes take 
place in the PFC and can result in various executive, cog-
nitive and affective dysfunctions (Figs. 5, 6) (e.g., [18, 76, 
114, 198]).
Effects of chronic stress on structure and function of the 
PFC are supported by human imaging studies. For exam-
ple, significant reductions in the gray matter of DL–PFC 
and ACC were found in subjects with long-term occupa-
tional stress by MRI-based voxel-based morphometry [12]. 
Subjects reporting more uncontrollable and overwhelm-
ing stressors displayed blunted neural responses in mPFC 
following feedback processing as established by fMRI. In 
another fMRI study, patients with MDD and a history of 
childhood maltreatment showed reduced functional con-
nectivity strength within the prefrontal-limbic-thalamic-
cerebellar circuitry and these reductions were significantly 
correlated with measures of childhood neglect [230]. Mal-
treated children had volume reductions in the medial orbit-
ofrontal cortex and middle temporal gyrus [44]. Similarly, 
early life stress in depressed patients decreased local con-
nectivity of the ventrolateral PFC and correlated negatively 
with global connectivity for the DL–PFC [28].
In summary, there is a clear effect of early life stress or 
stress in adulthood on reductions in volume and alteration 
in functional connectivity of the PFC and related cortical 
limbic regions. Interestingly, these effects are present not 
only in depression but also in healthy controls who were 
exposed either to occupational or early life stress.
Inflammatory changes and depression
Although inflammatory changes alone may not typically 
initiate pathology, emerging evidence indicates that sus-
tained inflammation can affect disease progression of vari-
ous brain disorders, and is implicated in depression etiology 
[42, 218]. When activated, cells of the immune system pro-
duce pro-inflammatory cytokines that can induce behavio-
ral withdrawal and activate the HPA axis [11]. Conversely, 
stress and/or elevated GC levels themselves are generally 
immunosuppressive and prevent the immune system from 
overshooting. Psychological stress is known to stimulate 
pro-inflammatory cytokine production in patients experi-
encing stress and anxiety, and elevations in interleukin-1β 
(IL-1β) and 6 (IL-6) and increases in macrophage activ-
ity have been reported in depression [42, 222]. Stress can 
provoke depression-like behaviors, mediated through the 
activation of inflammatory and anti-neurogenic mecha-
nisms and pathways, some of which are even normalized 
by antidepressants [105]. Inflammation can further affect 
hippocampal function and cognition [138, 240, 246] and 
reducing it by anti-inflammatory drugs restored functional 
and structural plasticity in animal models [56, 138].
Stress-related changes in PTSD
Post-traumatic stress disorder (PTSD) is a multisystem 
disorder with multiple comorbidities. PTSD patients have 
experienced severe, often life-threatening, episodes of 
stress that cause flashbacks, nightmares and sleep prob-
lems, emotional numbness or emotional outbursts, anhedo-
nia, inappropriate startle reflexes and problems with mem-
ory and concentration [21]. Notably, the HPA changes in 
PTSD indicate low cortisol levels consistent with increased 
glucocorticoid sensitivity. In one particularly intriguing 
experimental protocol, 40 pairs of identical twins were 
studied, one of whom participated in the Vietnam war 
while the other stayed at home. Of those who experienced 
combat, 43 % developed PTSD. They turned out to have 
smaller hippocampi, but their stay-at-home twin brother 
did too. In contrast, those who did not develop PTSD had 
larger hippocampi, and so did their stay-at-home twin 
as well. A small hippocampus thus seems to be present 
already prior to the stressful experience and in fact to infer 
an increased vulnerability to PTSD [69, 180]. This goes 
back to the idea of either genetic factors, or life history and 
shaping events during critical development periods, or an 
interaction between the two, determining hippocampal vol-
ume early in life, and putting the individual on a trajectory 
for (psycho)pathology [30, 124, 161].
Thus, it remains elusive whether hypercortisolism is 
indeed responsible for hippocampal shrinkage, since com-
bat-related PTSD is associated with decreased HPA axis 
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activity and steroid feedback super-sensitivity that often 
lasts for decades after the initial trauma. It has been pre-
sumed that early on in the process the HPA axis may have 
been strongly activated. This is based on the observation 
that soldiers who had undergone random bombardments 
in the Korean war displayed markedly increased levels 
of cortisol, with the highest levels of cortisol in soldiers 
who had been in the greatest danger. It has therefore been 
Fig. 5  Schematic representation of the connections between the pre-
frontal cortex, the stress response and the immune system and the 
changed interactions during conditions of chronic stress. At basal 
conditions (left panel), the right medial prefrontal cortex (mPFC) 
is mainly under tonic inhibition from its left counterpart. Modula-
tory inputs from the mPFC, amygdala and hippocampus to the PVN 
relay on the bed nucleus of the stria terminalis (BNST). Further-
more, whereas activation of the infralimbic cortex (IL) and amygdala 
increases PVN activity, activation of the cingulate (Cg) and prelim-
bic (PL) parts of the PFC and from the hippocampus decreases it. 
In basal conditions the parasympathetic tone of the autonomic nerv-
ous system predominates. After chronic stress (right panel), which 
elevates glucocorticoid levels, changes are induced in the brain that 
include a decreased volume and dendritic retraction in the mPFC and 
hippocampus, but opposite changes in the BNST and amygdala (see 
Fig. 4). Damage to the hippocampus may decrease the influence of 
this brain structure on the mPFC and BNST (dotted lines); as a result, 
a reduced activity of the mPFC (especially in the left hemisphere) 
may occur, but an overactivation of the amygdala and over the neu-
roendocrine and autonomic control centers (BNST/hypothalamus). 
This may trigger HPA axis dysfunction, increase corticosteroid lev-
els and activate the sympathetic nervous system, which, together, may 
induce immune dysregulation and contribute to behavioral dysfunc-
tion. Reproduced from [26], with permission
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hypothesized that high levels of cortisol at the time of the 
stressor would result in damage to the hippocampal neu-
rons that may persist for many years after the original 
trauma and that could lead to reductions in hippocampal 
volume and subsequent differences in feedback or stress 
responsivity. However, those victims of rape or motor 
vehicle accidents who later developed PTSD appeared 
to have—already a few hours after the traumatic event—
lower cortisol levels than victims who had no subsequent 
psychiatric disorder, or those who developed major depres-
sion. Yet, pituitary and adrenal hyperactivity to exogenous 
CRH and ACTH has been demonstrated in these patients. 
An increased sensitivity or up-regulation of GRs in PTSD 
and a pre-existing smaller hippocampal volume thus seems, 
at present, the best explanation [180, 239].
Stress-related effects: relation to sex, aging, Alzheimer’s 
disease and Cushing’s disease
Gender differences in depression: relationship with HPA 
axis activity
Gender differences in stress regulation have important 
implications for understanding the physiological differ-
ences in the male and female brain and their impact on vul-
nerability to stress disorders. Women are generally better 
at expressing emotions, tend to score higher on emotional 
ratings on, e.g., neuroticism [73] and have an increased risk 
of suffering from mood disorders. Morphometrical studies 
have shown sexual dimorphisms in several brain structures 
implicated in emotional processing, including the cingu-
late and ventrolateral prefrontal cortices (larger in women) 
and the medial temporal structures, including the amygdala 
and BST (larger in men) that are implicated in emotional 
processing [70]. These structural differences are thought to 
be programmed by sex steroids during early development 
[70].
The possible importance of fluctuating levels of sex 
hormones as a risk factor for depression is underlined by 
the higher prevalence of premenstrual depression, antepar-
tum or post-partum depression, and depression during the 
transition to menopause. Studies in rodents have further 
shown intrinsic differences in the way female and male 
brains respond to stress [113]. Human post-mortem brain, 
animal and cell-line studies confirm a key stimulating role 
of estrogens on CRH production, while androgens dimin-
ish CRH production [152]. These opposite effects on CRH 
neurons may underlie sex difference in the prevalence of 
depression.
Stress‑related changes in Alzheimer’s disease (AD)
Stressful life experiences are implicated in sporadic forms 
of AD. A considerable portion of AD patients hypersecrete 
glucocorticoids or are non-suppressors of plasma cortisol 
following dexamethasone administration [145, 169, 208, 
209]. Their GC levels generally correlate with their rates 
of cognitive impairment and the extent of neuronal remod-
eling [48, 89, 123]. The cognitive deficits in AD correlate 
primarily with hyperphosphorylated forms of the cytoskel-
etal protein tau, which, together with amyloid β (Aβ), has 
a pathogenic role in AD. Increased GC levels may not 
only induce hippocampal damage but can also potentiate 
Aβ toxicity [25, 91]. Conversely, dehydro-epiandrosterone 
(DHEA) and its sulphate (DHEAS) or GR blockade may 
exert a neuroprotective action [5, 141].
Some aging animals and mouse models of AD show 
changes in stress regulation too but also, in wild-type, 
middle-aged rats, chronic stress and GCs induce abnormal 
Fig. 6  Scheme representing the contrasting effects of chronic stress 
on dendritic spine numbers in the prefrontal cortex (PFC) and amyg-
dala. a A decrease in the number of spines occurs in pyramidal neu-
rons of the infralimbic cortex of rats after repeated restraint stress 
(21 days). b By contrast, chronic immobilization stress (10 days) 
triggers an increase in the number of spines in basolateral amygdala 
spiny neurons in rats. Amy amygdala, mPFC medial prefrontal cortex. 
Reproduced, with permission, from [26]
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hyperphosphorylation of Tau in the hippocampus and PFC, 
with parallel impairments of hippocampus- and PFC-
dependent behaviors. Exogenous GC application further 
potentiates the ability of centrally infused Aβ to induce 
hyperphosphorylation of Tau epitopes. Moreover, previ-
ous exposure to stress further aggravated the biochemical 
and behavioral effects of GCs in Aβ-infused animals [25, 
193]. Thus, stress and GC exposure may have a cumula-
tive impact on the onset and progression of AD pathol-
ogy. Tau hyperphosphorylation may be instrumental in the 
negative effects of stress and GC on cognition, initially by 
increasing the production of pathogenic products of amy-
loid precursor protein (APP), followed by up-regulation of 
Tau kinases such as GSK3β and cdk5 and aberrantly hyper-
phosphorylated Tau [199].
Stress‑related changes in Cushing’s syndrome
Cushing’s syndrome can occur after prolonged exposure 
to (tumor-derived) cortisol or synthetic steroids and usu-
ally induces some brain atrophy and cognitive dysfunction. 
Positive correlations exist between hippocampal volume 
and memory tests and negative ones with plasma cortisol 
levels. As at least partial recovery of brain shrinkage occurs 
after reversal of high GC exposure [19, 201] making mas-
sive, irreversible, cell loss unlikely [53, 75, 85, 242].
Effects of stress on structural and molecular plasticity
Traditionally, affective and stress-related brain disorders 
were explained by neurochemical (mainly monoaminergic) 
imbalances. More recent studies indicate that impairments 
in structural plasticity and volumetric changes of specific 
limbic areas also contribute to their pathophysiology. Vari-
ous candidate cellular substrates, like dendritic retraction, 
neuronal loss or glial changes have been proposed that are 
indeed all stress-sensitive [36, 127, 167]. Reciprocal rela-
tionships may exist between stress-related behaviors and 
changes in structural plasticity. Overall, it still remains 
unclear whether the above substrates should be classified 
as truly pathological or whether they may represent plastic 
and/or dynamic adaptations to a stressor that can to some 
extent be reversible.
Dendritic remodeling
One of the best known forms of structural plasticity is den-
dritic retraction that was first observed in CA3 and CA1 hip-
pocampal neurons following chronic stress exposure. At the 
structural level, prolonged exposure to high doses of corti-
costerone reduces apical (but not basal) dendritic complexity 
of CA3 pyramidal neurons [237] and a prolonged exposure 
to various types of chronic stress results in similar changes 
in different species [64, 129]. These changes in hippocam-
pal dendritic morphology generally need several weeks to 
develop. In addition, chronic stress also leads to a loss of 
mossy fiber synapses, increased surface area of the post-syn-
aptic density, and rearrangements of synaptic mitochondria 
and vesicles at the presynaptic terminals [176, 213].
Spine density
The effects of stress on spine density are less clear. While 
increase in the number of spines were reported on CA3 
pyramidal dendrites and in the size of the post-synaptic 
densities on CA1 synapses, others could not find changes 
in spine density [129] or reported a decrease in spines, 
that was notably rapidly reversible already after a recovery 
period or subsequent training [1, 176, 205]. Oscillating GC 
plasma concentrations along the circadian rhythm appear 
to be important for the elimination of spines present before 
motor learning, and also for the maintenance of new spines 
along with the retention of motor memory [115]. Spine 
elimination, but not their formation, was shown to require 
MR activation [115]. Together, these studies suggest that 
prolonged exposure to chronic stress and glucocorticoids 
markedly alters the number and morphology of both pre- 
and post-synaptic structural elements and thus strength of 
excitatory synapses in the hippocampus.
Dendritic spines are of particular relevance as they are 
critically involved in the storage of information and their 
density can be increased by stress under specific condi-
tions [212]. Pyramidal cells of the hippocampus and PFC 
respond with reduced dendritic complexity and spine loss 
to chronic stress [71, 164], both of which are reversible 
following a recovery period [71, 165], but other regions 
appear resistant [194]. Consistent with circuit-specific 
effects of stress (Fig. 5), also increases were found in the 
dendritic arborization of orbital frontal cortex neurons, an 
effect opposite to what is observed in other cortical neu-
ron populations. Interestingly, in the basolateral amygdala 
and nucleus accumbens (NAc), stress generally results in 
hypertrophy of dendritic arborization and increases in spine 
density (Fig. 6). In the amygdala, these changes do not nor-
malize following a recovery period after stress [137, 225]. 
In addition to changes in spine density, chronic unpredict-
able stress reduces density of synapses in the rat PFC [94]. 
Similar reductions in synaptic density and a lower expres-
sion of synaptic function-related genes occur in the DL–
PFC of MDD subjects [94].
Apoptosis, neuronal death and neuropil loss
According to the glucocorticoid cascade hypothesis, 
neuronal apoptosis may underlie hippocampal volume 
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shrinkage observed after stress [182]. Neuronal death has 
also been implicated in the cerebral shrinkage that occurs 
following prednisone administration and/or in the inflam-
matory changes in the cortex in depression [119, 134, 196, 
209]. However, initial histological and neuropathological 
examination of the hippocampus of depression models or 
from patients that had been depressed or were exposed to 
synthetic corticosteroids, could not support this notion. In 
hippocampi from established depressed patients, no indica-
tions for obvious neuronal loss or for significant neuropa-
thology could be found using a variety of relevant archi-
tectural, synaptic and glia markers [29, 117, 119, 142] 
(see Figs. 7, 8). In a very recent study, Boldrini et al. [17] 
reported fewer granule cells in the dentate gyrus of unmed-
icated depressed patients (without fewer neuronal progeni-
tor cells) suggesting that cell maturation or turnover defects 
in this plastic hippocampal subregion might be related to 
the duration of the illness. Notably, the hippocampal vol-
ume reductions present in Cushing’s disease were reversed 
after cessation of steroid exposure [204]. Similar find-
ings exist on ventricular enlargements that are reversible 
in certain conditions (e.g., following recovery from alco-
holism or prolonged steroid use), thereby challenging the 
hypothesis that ventricular enlargement predicts neuronal 
loss [210]. This agrees with the general clinical experience 
with depressive or Cushing’s patients, in which treatment 
or operation can relieve their depressive symptoms, several 
of the HPA alterations, and even the hippocampal shrink-
age, findings that would be hard to interpret had irrevers-
ible damage or massive cell loss been induced.
The incidence of apoptosis or cell loss in rodent stress 
models is rare and also seen after acute stress [79, 119, 
241]. Chronic stress changed apoptosis in tree shrews only 
in specific hippocampal subareas and was normalized by 
tianeptine treatment [118]. These effects also occurred in 
associated cortical areas and were consistent with a general 
anti-apoptotic mode of antidepressant action [118, 134]. 
This bears considerable relevance for the interpretation 
of structural and/or neuropathological studies on the hip-
pocampus in depression, where almost all patients gener-
ally receive antidepressant treatment [90, 117] and hence, 
effects of the disorder per se might be masked by the 
concomitant drug treatment. Yet, in drug-free, depressed 
patients [17], little differences were reported when com-
pared to patients on treatment [17], and hippocampal vol-
ume reductions were then present as well.
Adult hippocampal neurogenesis
Another, relatively novel, form of neuroplasticity is neu-
rogenesis that has been implicated in stress-induced hip-
pocampal volume changes. Adult neurogenesis refers to the 
production of new neurons, an event that continues to occur 
in the adult brain of several mammalian species, includ-
ing humans (Figs. 4, 9) [58, 120]. Neuron formation in the 
adult hippocampus received considerable attention during 
recent years and was proposed to contribute to depression 
etiology [96]. Although later studies suggested that neuro-
genesis was rather implicated in antidepressant drug actions 
[177], we still lack a coherent functional theory explain-
ing how exactly newborn neurons in the hippocampus can 
contribute to mood, or to specific symptoms of depression, 
besides their cognitive deficits, which are related too, but 
not specific to mood disorders. Although a reduced rate of 
neurogenesis may reflect impaired hippocampal plasticity, 
reductions in adult neurogenesis alone are unlikely to pro-
duce depression. Lasting reductions in the turnover rate of 
DG granule cells, however, will alter the average age and 
overall composition of the DG cell population and thereby 
influence properties and vulnerability of the hippocampal 
circuit.
Furthermore, neurogenesis is regulated by exercise, 
inflammation and antidepressants (Fig. 4) [37, 120, 146, 
177, 247] while stress potently inhibits neurogenesis in 
several species (Fig. 9) [120, 187]. Both psychosocial [74] 
and physical stressors [224] inhibit at least one or more 
phases of the neurogenesis process [74, 79]. Stress and 
GCs further interfere with most stages of neuronal renewal, 
proliferation, maturation and survival (Fig. 9) [79, 148, 
187, 236].
The neurogenic hypothesis of depression proposes that 
prolonged reductions in neurogenesis, e.g., induced by 
stress, may affect hippocampal structure and volume in 
depression, and that successful antidepressant treatment 
would require increases in neurogenesis [96, 120]. In pre-
clinical studies, the stress-induced suppression of DG neu-
rogenesis can be prevented by antidepressant treatments, 
which can also have direct neurogenic effects in naive ani-
mals. They can block effects on depressive-like behavior 
and may also restore plasticity outside the hippocampus 
[24, 133, 146].
Inflammation also affects neurogenesis. Microglia are 
considered instrumental given their homeostatic role in 
inflammatory signalling that may become maladaptive in 
the chronically stressed brain [72, 86, 155]. Under physi-
ological conditions, microglia exhibit a resting, ramified 
phenotype associated with the production of anti-inflam-
matory and neurotrophic factors, but when primed, e.g., 
by early life stress [51] or challenged by pathogens or 
damage during adult life, microglia can switch to an acti-
vated, amoeboid phenotype, that can initiate tissue repair, 
or rather produce cytokines that are detrimental for neu-
ronal function and viability [52, 56]. Specific subsets of 
cytokines can be proneurogenic [10] while others decrease 
neurogenesis through IL-1 [247]. Pro-inflammatory media-
tors can further restrict neurogenesis [56, 247].
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The exact underlying cellular mechanisms mediating the 
inhibitory effect of stress or inflammation on neurogenesis 
are largely unknown. Adrenal glucocorticoids have been sug-
gested as key players and MR, GR and NMDA receptors have 
been identified on progenitor cells [74]. At the same time, 
several examples exist of a longlasting inhibition of neuro-
genesis after an initial stressor, despite later normalized GC 
levels [187]. This suggests that while glucocorticoids may be 
involved in the initial suppression of cell proliferation, par-
ticularly in early life, when neurogenesis is abundant, they are 
not always necessary for the maintenance of this effect [74].
Stress also affects levels of various neurotransmitters 
implicated in the regulation of neurogenesis: GABA [67], 
serotonin, noradrenalin, dopamine [6], cannabinoids, opi-
oids and nitric oxide (see [6]). Stress further reduces the 
expression of several growth factors, such as brain-derived 
neurotrophic factor (BDNF), insulin-like growth factor-1 
(IGF-1), nerve growth factor (NGF), epidermal growth fac-
tor (EGF), and vascular endothelial growth factor (VEGF), 
that all can influence neurogenesis (see, e.g., [186] while 
gonadal steroids should not be neglected either [63]. 
The proximity of the precursors to blood vessels further 
Fig. 7  Photomicrographs of 
Nissl stained sections from the 
hippocampus of a depressed 
patient (a, b), a steroid-treated 
patient (c, d) and a control 
subject (e, f). b, d, f Shows 
the CA3 area of the same 
patients at higher magnification. 
Although some rare apoptotic 
cells (brown TUNEL-positive 
cells indicated by arrows in g 
and h, compared to intact, non 
stained neuronal nuclei nearby 
(arrowhead)) were seen outside 
of subregions predicted to be at 
risk for glucocorticoid overex-
posure like the dentate gyrus or 
entorhinal cortex, no morpho-
logical evidence for neuronal 
damage or massive cell loss was 
observed in any of the groups. 
Bar indicates 710 μm in (a) and 
45 μm in (b). Reproduced, with 
permission, from [117, 142]
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suggests a strong interaction with the vasculature and it is 
this population that is particularly sensitive to stress [80].
Although there is extensive preclinical evidence that anti-
depressants affect hippocampal neuroplasticity, information 
regarding the possible impact of medication on hippocam-
pal volume in MRI studies of MDD patients is limited. A 
recent study by Huang et al. [90], found smaller DG vol-
umes in unmedicated depressed patients and a post-mortem 
analysis reported the same [17] which would be consistent 
with the neurogenic hypothesis of depression. Interestingly, 
both subfield and posterior hippocampal volume reductions 
were reported that were only seen in unmedicated depres-
sion but were absent in patients treated with antidepressants. 
Although it is so far not possible to reliably detect ongoing 
neurogenesis in vivo [35, 131], these data are consistent 
with preclinical studies demonstrating subregional specific 
effects of stress and its modulators on neurogenesis, and/or 
on hippocampal functionality [99].
While neurogenesis in the mature human hippocampus 
is a rare event [14, 58, 101], changes have been reported 
Fig. 8  Immunohistochemical staining for synaptophysin (a, c, e) 
and for the neuronal growth-related phosphoprotein B-50 (b, d, f) 
in the hippocampus of a, b a depressed patient, c, d a steroid-treated 
patient and e, f a control subject. No marked qualitative difference 
is observed between the overall immunohistochemical staining pat-
terns of the groups in the hippocampal subarea CA3 and the molec-
ular layer of the dentate gyrus. Bar in e represents 50 μm, bar in f 
115 μm. Reproduced, with permission, from [117, 142]
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following antidepressant treatment in middle aged, but not 
older depressed patients [15, 16, 121]. In a recent post-
mortem study of major depressed patients, the volume of 
the histologically defined dentate gyrus was in fact 68 % 
larger in SSRI-treated depressed subjects [16]. SSRI treat-
ment also substantially increased neural progenitor cells 
(NPCs) in the dentate gyrus [15], although this was not rep-
licated by others [170] and may depend on the age of the 
patients [121].
The glutamatergic and GABAergic systems in depression
The glutamatergic pathway shows alterations in patients 
with mood disorder [9, 174]. Particularly, since glutamate 
stimulates the HPA axis antiglutamatergic agents, like keta-
mine [95, 244] are considered promising targeta for new 
antidepressants. In patients with MDD, glutamine syn-
thetase (GS) transcripts were down-regulated in the anterior 
cingulate cortex and dorsolateral PFC [27]. The expression 
of glutamate transporters, the excitatory amino acid trans-
porters (EAAT), EAAT1, EAAT2 are reduced frontal brain 
regions in MDD [27]. Accumulations of extracellular glu-
tamate may not only perturb the ratio of excitatory–inhibi-
tory neurotransmitters [34], but could also damage neurons 
and glia.
Regarding the GABAergic system, the majority of stud-
ies revealed lower GABA levels in the brain of depressed 
patients, suggesting a hypoactive GABAergic neurotrans-
mission, including the PVN [9, 126]. GABA also inhibits 
the HPA axis in the hypothalamus [103] and GABAergic 
drugs can help maintain a positive response during antide-
pressant treatment [126].
Glial plasticity
During recent years, also glial abnormalities have been 
implicated in the pathophysiology of mood disorders. 
Glial cells slightly outnumber neurons in the human 
hippocampus and constitute a substantial volume frac-
tion. During pathophysiological conditions, specific glial 
subtypes may become activated, or may die, or, similarly 
to the dendritic debranching documented in neurons, may 
retract their elaborate branching processes, and thereby 
reduce hippocampal volume. A considerable proportion 
of the astrocytes further express GRs in the rodent [66] 
Fig. 9  Chronic stress inhibits neurogenesis in the adult hippocampal 
dentate gyrus. Representative confocal images of newborn neurons 
in the hippocampus of adult mice with low (a) and high magnifica-
tion (b). A mixture of retroviruses expressing green and red fluores-
cent protein (CAG-IRES-GFP and CAG-IRES-RFP) was injected 
into the dentate gyrus of adult mice to label the newly born cells. 
Double-transduced cells are in yellow and DAPI is in blue. B. Czéh, 
D. Refojo, and D.C. Lie unpublished observations. Scale bars a 
50 μm, b 20 μm. c Chronic stress inhibits both the proliferation rate 
and the survival rate of the newly generated cells in the hippocam-
pal dentate gyrus of adult rats as it was shown with BrdU-labeling 
in a chronic social defeat stress model (modified fom [39]). Data are 
mean ± SEM, group sizes n = 6 rats/group, ***p < 0.001. Similar 
changes are seen in depressed individuals [16, 121] and treatment 
with some, but not all, antidepressants can normalize these changes 
[16, 37, 120]
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and human hippocampus [231] and similar to neurons, 
these cells are stress responsive too. Typically, astrocytes 
are identified by their GFAP (glial fibrillary acidic pro-
tein) expression and stress modulates GFAP expression in 
rodents: while acute physical stress increase GFAP immu-
noreactivity in several brain regions [106], chronic stress 
reduced GFAP mRNA and protein expression levels in the 
prefrontal cortex and hippocampus [3]. As corticosterone 
lowers GFAP levels in rat brain [144], elevated glucocorti-
coids are likely instrumental in these effects.
Further studies demonstrated that in laboratory animals, 
exposure to long-term stress, either during early life or 
adulthood, decreased number and somal volume of GFAP-
positive astrocytes in the hippocampus and in several 
other stress-related brain areas [38, 111]. This implied that 
chronic stress may cause astrocytic loss, while more recent 
experiments did not substantiate that [216]. For example, in 
vitro experiments showed that dexamethasone treatment of 
astrocytes, derived from hippocampal primary cell cultures, 
results in growth inhibition and moderate activation of cas-
pase 3, which is not followed by apoptosis [241], suggest-
ing that hippocampal astrocytes are resistant to glucocorti-
coid-induced apoptosis.
A recent in vivo study suggests that the reduced num-
ber of GFAP-positive cells after stress may not reflect cell 
death. By comparing the results of different labeling meth-
ods, it was found that chronic stress was associated with 
a decrease in GFAP-+ cell numbers, but there was no 
indication for astrocytic cell loss based on Nissl staining 
or S100ß-immunoreactivity [216]. This latter study also 
showed that astrocytes respond to chronic stress by reor-
ganizing their cellular morphology and reducing the length, 
complexity and volume of their processes [216].
Chronic stress can also reduce the proliferation rate of 
glial cells. This was shown in the medial prefrontal cortex 
of rats subjected to 5 weeks of social defeat, or to chronic 
unpredictable stress or after chronic corticosterone admin-
istration [7, 39]. Similarly, prolonged and elevated gluco-
corticoid treatment inhibits NG2-positive cell prolifera-
tion in the adult rat hippocampus [144] reflecting changes 
in oligodendrocyte precursors or in a distinct mature glial 
type. Chronic stress also promotes significant structural 
remodeling of microglia, and can enhance the release of 
pro-inflammatory cytokines from microglia [227].
Finally, glial cells, especially astrocytes, are key com-
ponents of the “neurogenic niche” that provides the neces-
sary local microenvironment for generation of neurons in 
specific brain areas. They support maturation and integra-
tion of newborn neurons, both physically and by releasing 
a cocktail of growth factors and cytokines. Together, this 
implies that GCs not only are influenced by stress, but 
also stimulate interactions between astrocytes and neural 
progenitors.
In humans, post-mortem analysis of tissue from 
depressed patients has revealed reductions in glial numbers 
in the amygdala and prefrontal, orbitofrontal and cingulate 
cortices [20, 32, 149]. Accumulating data demonstrates that 
not only astrocytic cell numbers are reduced in depressed 
patients, but several typical structural and functional astro-
cytic markers as well, like GFAP, gap junction proteins, the 
water channel aquaporin-4 (AQP4), a calcium-binding pro-
tein S100B and glutamatergic markers including the excita-
tory amino acid transporters 1 and 2 (EAAT1, EAAT2) and 
glutamine synthetase [167].
In contrast, studies on post-mortem hippocampal sam-
ples so far failed to find significant reductions in neuron 
or glial cell numbers, while confirming the volume reduc-
tion in depressed patients [29]. One should add that besides 
astrocytes and oligondendrocytes, also microglia have also 
been implicated in pathological mood regulation [55, 60]. 
In vivo imaging studies in depressed patients demonstrate 
white matter abnormalities suggesting a contribution of oli-
godendrocytes to MDD etiology. MRI and also diffusion 
tensor imaging studies revealed white matter hyperintensi-
ties particularly in elderly subjects with late-life depression 
(reviewed in [55]) which was substantiated by post-mortem 
data reporting lower density of oligodendrocytes in the 
MDD brain and a reduced expression of oligodendrocyte-
specific gene transcripts [55]. Animal models based on 
chronic stress paradigms also showed cellular and molec-
ular changes in limbic structures that indicate an involve-
ment of oligodendrocytes [39, 43, 207].
Water content, volume changes and altered vasculature
The controversial findings on hippocampal volume decrease 
without significant cell loss might also be explained by 
shifts in water content and the volumetric reduction of lim-
bic structures is indeed often accompanied by enlarged cer-
ebral ventricles [97]. In support, significantly shortened T1 
relaxation times were found for the hippocampus, especially 
in elderly depressed patients, indicative of differences in 
hippocampal water content. A recent study used multimodal 
in vivo imaging, incorporating structural magnetic reso-
nance imaging (MRI), and MR spectroscopy (1H-MRS) in 
rats exposed to ethanol [242]. While MRI revealed expan-
sion of ventricles, volume changes in dorsal or ventral hip-
pocampi, caudate or thalamus were not detected. Also, all 
MR parameters returned to baseline with 7 days of recovery 
[242]. Thus, the rapid recovery of ventricular volume and 
the absence of detectable volume reductions in brain regions 
adjacent to the ventricles argue against neuronal or tissue 
atrophy as a mechanism to explain ventricular expansion 
but rather suggest lower tissue water content. Thus, a rapid 
fluid redistribution may be followed by compensatory ven-
tricular volume changes in stress-related psychopathologies.
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Water homeostasis is largely regulated by aquaporin 
water channels. In the CNS, their major representative is 
AQP4 which is expressed in the end-feet of astrocytic pro-
cesses, but not in neurons [211]. In the human orbitofron-
tal cortex (Brodmann’s area 47; gray matter), the density 
of AQP4 immunoreactive astrocytic end-feet was reduced 
by 50 % in patients with major depression [168] while the 
coverage of vessels by GFAP-immunoreactive processes 
did not differ from controls. These data indicate possible 
disturbances in water homeostasis, at least in this brain 
region.
Finally, a recent study revealed that stress reduced num-
bers of microvessels and capillarization in the hippocampi 
of stressed rats [41, 80] which coincides with clinical stud-
ies and metareviews indicating that increased psychologi-
cal distress and depression are associated with increased 
stroke risk and mortality [150].
Conclusions
Exposure to chronic or severe stress has profound effects 
on the structural and functional integrity of limbic brain 
areas that not only coordinate the stress response, but are 
also exposed to the altered expression levels of different 
hormones, neurotransmitters and trophic factors. The cen-
tral role of the HPA axis in these events has been most thor-
oughly investigated. Current experimental, post-mortem 
and in vivo imaging techniques have revealed various sub-
tle morphological changes detectable both at the cellular 
level (affecting spines, dendrites, endothelial cells of the 
vasculature and glial and neuronal cell numbers), and in the 
gross morphology of specific brain areas (MRI findings). 
These changes thus appear to affect almost all cellular 
components of the CNS and many efforts are now under-
taken to uncover the exact molecular mechanisms. While 
earlier studies highlighted disturbances in the monoamin-
ergic systems, the glutamatergic and GABAergic systems 
receive attention too.
Most of the cellular responses to stress are initially 
plastic in nature and can normalize following appropriate 
recovery periods. These changes, particularly during the 
early phase, are often adaptive and essential for success-
ful coping with stress. It is still very difficult to pinpoint 
when adaptive changes turn into maladaptive and/or path-
ological, and when systems start to deteriorate. Notably, 
many stress-induced morphological changes are specific to 
selected brain areas, and even to specific cell types, where 
they often correlate well with the functional disturbances of 
that given brain structure.
Finally, in humans, severe or repeated stress often con-
tributes to the development, or can worsen the outcome, 
of psychopathology. Here, it is difficult to separate initial 
structural and/or neuropathological changes specific to the 
disease from the ones that result from the (additional) stress 
exposure per se.
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